A carregar...
Structure-based design of inhibitors with improved selectivity for steroidogenic cytochrome P450 17A1 over cytochrome P450 21A2
Inhibition of androgen biosynthesis is clinically effective for treating androgen-responsive prostate cancer. Abiraterone is a clinical first-in-class inhibitor of cytochrome P450 17A1 (CYP17A1) required for androgen biosynthesis. However, abiraterone also causes hypertension, hypokalemia, and edema...
Na minha lista:
| Publicado no: | J Med Chem |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6367708/ https://ncbi.nlm.nih.gov/pubmed/29792703 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jmedchem.8b00419 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|